The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study.
 
David Silva Moura
Honoraria - Tecnofarma
Research Funding - Eisai (Inst); Immix BioPharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Pfizer; PharmaMar
 
Juan A. Cordero Varela
No Relationships to Disclose
 
Ramiro Alvarez
No Relationships to Disclose
 
Carolina Agra Pujol
No Relationships to Disclose
 
Francisco Izquierdo
No Relationships to Disclose
 
Rafael Ramos
No Relationships to Disclose
 
Luis Ortega
No Relationships to Disclose
 
Francisco Martin-Davila
No Relationships to Disclose
 
Nieves Hernandez Leon
No Relationships to Disclose
 
Cleofe Romagosa
No Relationships to Disclose
 
Maria Ángeles Vaz-Salgado
No Relationships to Disclose
 
Javier Lavernia
No Relationships to Disclose
 
Silvia Bague
Travel, Accommodations, Expenses - PharmaMar
 
Empar Mayodormo-Aranda
No Relationships to Disclose
 
Jose Lucinio Mondaza-Hernandez
No Relationships to Disclose
 
Marta Renshaw-Calderon
No Relationships to Disclose
 
Nadia Hindi
Honoraria - PharmaMar; Tecnofarma
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Research Funding - Adaptimmune (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Pfizer (Inst); CEBIOTEX (Inst); Deciphera (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Claudia Valverde Morales
No Relationships to Disclose
 
Javier Martínez-Trufero
Consulting or Advisory Role - Boehringer Ingelheim Spain; Deciphera; Eisai; GlaxoSmithKline; PharmaMar
Research Funding - Ayala Pharmaceuticals (Inst); BionTech (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Kariopharm Therapeutics (Inst); Lilly (Inst); PharmaMar (Inst); Syneos Health (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Merck; PharmaMar; PharmaMar; Roche
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar